Home > > > > > Report Detail

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics

Publisher Name :
Date: 01-Feb-2015
No. of pages: 1028
Inquire Before Buying

The Licensing Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why companies enter licensing deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of licensing dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where licensing forms a part.

Chapter 4 provides a review of the leading licensing deals since 2010. Deals are listed by headline value, signed by bigpharma, most active big pharma, signed by big biotech, most active big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive review of licensing financials for deals announced since 2010, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

Chapters 6 and 7 provide a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of licensing deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of licensing deals signed and announced since 2010 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing dealmaking, enabling thorough learning, education and due diligence prior and during the licensing dealmaking process.

Report scope

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading life science companies worldwide.

Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:


  • Trends in licensing dealmaking in the biopharma industry since 2010

  • Analysis of licensing deal structure

  • Case studies of real-life licensing deals

  • Comprehensive listing of licensing deals since 2010

  • Access to licensing contract documents

  • Key financial bnchmarks for headline, upfront, milestone and royalty rates

  • The leading licensing deals by value since 2010

  • Most active licensing dealmakers since 2010

  • The leading licensing partnering resources


In Licensing Terms and Agreements in Pharma, Biotech and Diagnostics available deals and contracts are listed by:

  • Company A-Z

  • Headline value

  • Therapeutic area

  • Technology type


Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

Benefits

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:


  • In-depth understanding of licensing partnering deal trends since 2010

  • Insight into the terms included in a licensing agreement, together with real world clause examples

  • Identify leading licensing deals by value since 2010

  • Identify the most active licensing dealmakers since 2010

  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates

  • Full listing of licensing deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus

  • Comprehensive access to over 4,000 licensing deals entered into by the world's biopharma companies, together with contract documents if available

  • Detailed access to actual licensing contracts entered into by the leading fifty big pharma and big biotech companies

  • Understand the key deal terms companies have agreed in previous deals

  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking
2.1. Introduction
2.2. Definition of licensing deals
2.3. Success factors for licensing deals
2.4. When licensing can be useful
2.5. Attributes of licensing deals
2.6. Trends in licensing deals since 2010
2.7. Option to license
2.8. Adding co-promotion to the mix
2.9. The future of licensing deals

Chapter 3 - Overview of licensing deal structure
3.1. Introduction
3.2. Pure versus multi-component licensing deals
3.3. Pure licensing agreement structure
3.3.1. Example licensing agreements
3.3.1.a. Case study 1: Ignyta - Nerviano Medical Sciences - November 2013
3.3.1.b. Case study 2: Sanofi - Pozen - September 2013
3.4. Licensing rights as part of a wider alliance agreement
3.4.1. Example licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics - UniQure - January 2014
3.4.1.b. Case study 4: Kyowa Hakko Kirin - Ultragenyx Pharmaceuticals - September 2013
3.4.2. Example licensing option right clauses
3.4.2.a. Case study 5: Forest Laboratories - Trevena - May 2013
3.4.2.b. Case study 6: Abbvie - Receptos - March 2013

Chapter 4 - Leading licensing deals
4.1. Introduction
4.2. Top licensing deals by value
4.3. Most active licensing dealmakers
4.3.1 Most active licensing dealmakers by therapy
4.3.2. Most active licensing dealmaker by stage of development
4.4. Big pharma licensing deal activity
4.4. Big biotech licensing deal activity

Chapter 5 - Licensing deal term benchmarks
5.1. Introduction
5.1.2. Licensing headline values
5.1.2. Licensing upfront payments
5.1.3. Licensing milestone payments
5.1.4. Licensing royalty rates

Chapter 6 - Big pharma licensing deals
6.1. Introduction
6.2. How to use licensing deals
6.3. Big pharma company licensing agreement listings

Chapter 7 - Big biotech licensing deals
7.1. Introduction
7.2. How to use licensing deals
7.3. Big biotech licensing agreement listings

Chapter 8 - Licensing contract directory 2010-2014
8.1 Introduction
8.2 By company A-Z
8.3. By therapy area
8.4. By stage of development at signing
8.5. By technology area

Appendix
Appendix 1 - Resources
Appendix 2 - Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form - Reports

Additonal appendices - see separate PDF documents:
Appendix 1 - Licensing dealmaking - by financial disclosure
Appendix 2 - Licensing dealmaking - by companies A-Z
Appendix 3 - Licensing dealmaking - by stage of development
Appendix 4 - Licensing dealmaking - by therapeutic target
Appendix 5 - Licensing dealmaking - by technology type

List of Figures

Figure 1: Definition of licensing
Figure 2: Situations where licensing can prove useful
Figure 3: Key attributes of a licensing deal
Figure 4: Trends in licensing deal announcements, 2010-2014
Figure 5: Licensing deals signed at each phase of development, 2010-2014
Figure 6: Licensing deals by therapy area, 2010-2014
Figure 7: Licensing agreements - what should a contract include?
Figure 8: Components of the licensing deal structure
Figure 9: Top licensing deals by value since 2010 exceeding $1bn
Figure 10: Most active licensing dealmakers 2010-2014
Figure 11: Most active licensing dealmakers 2010-2014 by therapy area
Figure 12: Most active licensing dealmakers 2010-2014 - by stage of development
Figure 13: Big pharma - top 50 - licensing deals 2010 to 2014
Figure 14: Big pharma licensing deal frequency - 2009 to 2014
Figure 15: Big biotech - top 50 - licensing deals 2009 to 2014
Figure 16: Big biotech licensing deal frequency - 2009 to 2014
Figure 17: Licensing deal headline value distribution, US$million - discovery stage
Figure 18: Licensing deal headline value distribution, US$million - preclinical stage
Figure 19: Licensing deal headline value distribution, US$million - phase I stage
Figure 20: Licensing deal headline value distribution, US$million - phase II stage
Figure 21: Licensing deal headline value distribution, US$million - phase III stage
Figure 22: Licensing deal headline value distribution, US$million - regulatory stage
Figure 23: Licensing deal headline value distribution, US$million - marketed stage
Figure 24: Summary median licensing headline value by stage of development, 2010-2014
Figure 25: Licensing deal upfront payment distribution, US$million - discovery stage
Figure 26: Licensing deal upfront payment distribution, US$million - preclinical stage
Figure 27: Licensing deal upfront payment distribution, US$million - phase I stage
Figure 28: Licensing deal upfront payment distribution, US$million - phase II stage
Figure 29: Licensing deal upfront payment distribution, US$million - phase III stage
Figure 30: Licensing deal upfront payment distribution, US$million - regulatory stage
Figure 31: Licensing deal upfront payment distribution, US$million - marketed stage
Figure 32: Summary median licensing upfront payments by stage of development, 2010-2014
Figure 33: Licensing deal milestone distribution, US$million - discovery stage
Figure 34: Licensing deal milestone distribution, US$million - preclinical stage
Figure 35: Licensing deal milestone distribution, US$million - phase I stage
Figure 36: Licensing deal milestone distribution, US$million - phase II stage
Figure 37: Licensing deal milestone distribution, US$million - phase III stage
Figure 38: Licensing deal milestone distribution, US$million - regulatory stage
Figure 39: Licensing deal milestone distribution, US$million - marketed stage
Figure 40: Licensing deals with royalty rates, %
Figure 41: Licensing deal royalty rate distribution, US$million - discovery stage
Figure 42: Licensing deal royalty rate distribution, US$million - preclinical stage
Figure 43: Licensing deal royalty rate distribution, US$million - phase I stage
Figure 44: Licensing deal royalty rate distribution, US$million - phase II stage
Figure 45: Licensing deal royalty rate distribution, US$million - phase III stage
Figure 46: Licensing deal royalty rate distribution, US$million - regulatory stage
Figure 47: Licensing deal royalty rate distribution, US$million - marketed stage
Figure 48: Summary median licensing royalty rate by stage of development, 2010-2014
Figure 49: Online partnering resources
Figure 50: Deal type definitions

  • Licensing Terms and Agreements in Pharma, Biotech and Diagnostics
    Published: 01-Feb-2015        Price: US 3495 Onwards        Pages: 1028
    The Licensing Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies. The report provides a detailed understand and analysis of how and why companies enter licensing deals. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you......
  • Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
    Published: 01-Feb-2015        Price: US 1995 Onwards        Pages: 1325
    The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. Revised and updated 11th edition, includes: Trends in co-promotion and co-marketing deals Co-promotion and co-marketing agreement structure Co-promotion and co-......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs